TY - JOUR
T1 - New Drugs for Atherosclerosis
AU - Bruikman, Caroline S.
AU - Stoekenbroek, Robert M.
AU - Hovingh, G. Kees
AU - Kastelein, John P.
PY - 2017
Y1 - 2017
N2 - Atherosclerosis, the underlying process that ultimately leads to clinical cardiovascular disease (CVD), is caused by the multifactorial interaction of various conditions, and dyslipidemia is widely acknowledged as 1 of the crucial risk factors in this process. Statin drugs have been shown to decrease low-density lipoprotein cholesterol and CVD morbidity as well as mortality and are therefore pivotal in CVD prevention. Despite the use of statin drugs, CVD remains a leading cause of mortality worldwide, which suggests that additional lipid-lowering therapies are warranted. Several novel therapeutic agents, which are described in this review, are now well on their way in their respective development paths and might revolutionize anti-atherosclerotic drug therapy
AB - Atherosclerosis, the underlying process that ultimately leads to clinical cardiovascular disease (CVD), is caused by the multifactorial interaction of various conditions, and dyslipidemia is widely acknowledged as 1 of the crucial risk factors in this process. Statin drugs have been shown to decrease low-density lipoprotein cholesterol and CVD morbidity as well as mortality and are therefore pivotal in CVD prevention. Despite the use of statin drugs, CVD remains a leading cause of mortality worldwide, which suggests that additional lipid-lowering therapies are warranted. Several novel therapeutic agents, which are described in this review, are now well on their way in their respective development paths and might revolutionize anti-atherosclerotic drug therapy
U2 - https://doi.org/10.1016/j.cjca.2016.09.010
DO - https://doi.org/10.1016/j.cjca.2016.09.010
M3 - Review article
C2 - 27993452
SN - 0828-282X
VL - 33
SP - 350
EP - 357
JO - Canadian Journal of Cardiology
JF - Canadian Journal of Cardiology
IS - 3
ER -